Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - donepezil hydrochloride monohydrate, quantity: 10.43 mg (equivalent: donepezil hydrochloride, qty 10 ) - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin - treatment of mild, moderate and severe alzheimer's disease.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - memantine hydrochloride, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - treatment of the symptoms of moderately severe to severe alzheimer's disease.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - paracetamol, quantity: 325 mg; tramadol hydrochloride, quantity: 37.5 mg - tablet, film coated - excipient ingredients: powdered cellulose; magnesium stearate; macrogol 6000; sodium starch glycollate type a; titanium dioxide; hypromellose; pregelatinised maize starch; purified talc; iron oxide yellow; lactose monohydrate; maize starch; propylene glycol - zaldiar is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - valaciclovir hydrochloride hydrate, quantity: 556.275 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of >15ml/min. prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - moxonidine, quantity: 200 microgram - tablet, film coated - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; povidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxonidine gh is indicated for the treatment of hypertension

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - moxonidine, quantity: 400 microgram - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; lactose monohydrate; povidone; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - moxonidine gh is indicated for the treatment of hypertension

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; colloidal anhydrous silica; magnesium stearate; crospovidone; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; hyprolose; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - lacosam tablets are indicated as: ? monotherapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; crospovidone; magnesium stearate; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; lecithin; indigo carmine aluminium lake - lacosamide lupin tablets are indicated as: ? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.